Ivermectin Medical Valley

Ivermectin, the active ingredient in Ivermectin Medical Valley, is an anthelmintic presented as a tablet for oral use. It treats a range of parasitic infections such as onchocerciasis, strongyloidiasis, scabies, pediculosis and other helminth infections in adults and children.

GNH USA supplies Ivermectin Medical Valley as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin is an antiparasitic agent used to treat infections caused by various helminths and ectoparasites. - Onchocerciasis: reduces microfilarial load and prevents disease progression. - Strongyloidiasis: eradicates intestinal Strongyloides stercoralis infection. - Scabies: eliminates Sarcoptes scabiei mites and resolves skin lesions. - Pediculosis: kills head lice and nits, stopping infestation spread. - Other helminth infections: provides broad-spectrum activity against multiple nematode species.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: transient feeling of light‑headedness. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools occurring shortly after dosing. - Abdominal pain: cramping or discomfort in the stomach area. - Pruritus: itching sensation, often related to parasite die‑off. - Headache: mild to moderate tension‑type headache.

Serious or Rare Side Effects: - Severe skin reactions: including rash or Stevens‑Johnson syndrome. - Hepatotoxicity: elevated liver enzymes or liver injury. - Visual disturbances: blurred vision or optic neuritis. - Seizures: rare neurologic events, especially in high doses. - Anaphylaxis: acute allergic reaction requiring emergency care. - Cardiovascular collapse: hypotension or shock in extreme cases.

Before prescribing Ivermectin, consider patient‑specific factors and safety measures. - Pregnancy: safety not established; avoid unless benefits outweigh potential risks. - Breastfeeding: unknown excretion in milk; consider discontinuation or monitor infant. - Renal or hepatic impairment: use with caution and adjust dose if necessary. - Concomitant medications: review for potential interactions, especially CYP3A4 inhibitors. - Pediatric use: dosing must be determined by a qualified prescriber. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Ivermectin may interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ivermectin plasma concentrations. - P‑glycoprotein inhibitors (e.g., verapamil, quinidine): can raise systemic exposure.

Moderate Interactions (Monitor Closely): - Warfarin: potential enhancement of anticoagulant effect, monitor INR. - Other antiparasitics: may increase gastrointestinal side effects. - CNS depressants (e.g., benzodiazepines): may potentiate dizziness or sedation. - Statins metabolized by CYP3A4: monitor for muscle toxicity. - Antiepileptic drugs: may alter seizure threshold, observe clinical response.